Healthcare provider profile · identity verified

Samy B Gergis, MD

Family Practice · YORK, PA · NPI 1780683300

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	579	161
Omeprazole	Omeprazole	339	96
Simvastatin	Simvastatin	304	83
Amlodipine Besylate	Amlodipine Besylate	284	86
Levothyroxine Sodium	Levothyroxine Sodium	276	73
Metformin Hcl	Metformin Hcl	261	71
Hydrochlorothiazide	Hydrochlorothiazide	255	72
Losartan Potassium	Losartan Potassium	244	68
Metoprolol Succinate	Metoprolol Succinate	242	69
Sertraline Hcl	Sertraline Hcl	233	62
Lisinopril	Lisinopril	225	67
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	176	49
Metoprolol Tartrate	Metoprolol Tartrate	169	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	142	39
Clopidogrel	Clopidogrel Bisulfate	108	32
Furosemide	Furosemide	103	28
Pantoprazole Sodium	Pantoprazole Sodium	93	30
Tamsulosin Hcl	Tamsulosin Hcl	91	28
Gabapentin	Gabapentin	83	25
Albuterol Sulfate Hfa	Albuterol Sulfate	79	39
Eliquis	Apixaban	79	17
Atenolol	Atenolol	75	21
Glipizide	Glipizide	75	19
Allopurinol	Allopurinol	70	16
Alendronate Sodium	Alendronate Sodium	67	22
Donepezil Hcl	Donepezil Hcl	67	16
Metformin Hcl Er	Metformin Hcl	64	17
Rosuvastatin Calcium	Rosuvastatin Calcium	61	17
Enalapril Maleate	Enalapril Maleate	58	12
Glimepiride	Glimepiride	56	15
Synthroid	Levothyroxine Sodium	52	16
Prednisone	Prednisone	49	43
Finasteride	Finasteride	48	16
Hydralazine Hcl	Hydralazine Hcl	46	14
Jardiance	Empagliflozin	46	11
Celecoxib	Celecoxib	45	22
Famotidine	Famotidine	41	13
Pravastatin Sodium	Pravastatin Sodium	41	suppressed
Trazodone Hcl	Trazodone Hcl	40	13
Oxybutynin Chloride	Oxybutynin Chloride	39	suppressed
Diclofenac Sodium	Diclofenac Sodium	37	16
Montelukast Sodium	Montelukast Sodium	37	12
Fenofibrate	Fenofibrate	36	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	suppressed
Breo Ellipta	Fluticasone/Vilanterol	35	suppressed
Lovastatin	Lovastatin	35	suppressed
Meclizine Hcl	Meclizine Hcl	34	12
Carvedilol	Carvedilol	32	suppressed
Trulicity	Dulaglutide	31	suppressed
Warfarin Sodium	Warfarin Sodium	31	13
Xarelto	Rivaroxaban	31	12
Carbidopa-Levodopa	Carbidopa/Levodopa	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Lorazepam	Lorazepam	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Glipizide Er	Glipizide	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	28	suppressed
Potassium Chloride	Potassium Chloride	28	suppressed
Amoxicillin	Amoxicillin	27	21
Fluticasone Propionate	Fluticasone Propionate	27	13
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	27	suppressed
Bupropion Hcl	Bupropion Hcl	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Meloxicam	Meloxicam	25	15
Ozempic	Semaglutide	25	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	24	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Nitroglycerin	Nitroglycerin	24	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Terazosin Hcl	Terazosin Hcl	23	suppressed
Azithromycin	Azithromycin	21	19
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Raloxifene Hcl	Raloxifene Hcl	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Chlordiazepoxide Hcl	Chlordiazepoxide Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	15
Valsartan	Valsartan	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Irbesartan	Irbesartan	17	suppressed
Mometasone Furoate	Mometasone Furoate	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	11
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	16	suppressed
Cefuroxime	Cefuroxime Axetil	15	15
Clonazepam	Clonazepam	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Cephalexin	Cephalexin	14	11
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Nadolol	Nadolol	12	suppressed
Risedronate Sodium	Risedronate Sodium	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error